سعر Xarelto 10 mg 10 f.c. tab 2026
- المادة الفعالة: Rivaroxaban
- Bayer Healthcare
- عن طريق الفم
الفئة: مضاد للتخثر
دواعي استعمال Xarelto 10
- Prophylaxis of deep vein thrombosis after hip or knee replacement surgeryالفئة: AdultsDailyMed (U.S. National Library of Medicine)
- Reduction in the risk of recurrence of DVT and/or PE after at least 6 months of standard anticoagulant treatmentالفئة: AdultsDailyMed (U.S. National Library of Medicine)
- Prophylaxis of deep vein thrombosis after hip or knee replacement surgeryPopulation: AdultsDailyMed (U.S. National Library of Medicine)
- Reduction in the risk of recurrence of DVT and/or PE after at least 6 months of standard anticoagulant treatmentPopulation: AdultsDailyMed (U.S. National Library of Medicine)
معلومات الدواء
التفاصيل الكاملةالآثار الجانبيةSide effects
- The most common adverse reactions are bleeding complications.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- The most common adverse reactions are bleeding complications.International label, same formulation · DailyMed (U.S. National Library of Medicine)
موانع الاستعمالContraindications
- Active pathological bleeding.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Lesion or condition at significant risk of major bleeding; concomitant treatment with any other anticoagulant except when switching; hepatic disease associated with coagulopathy (incl. Child-Pugh B and C cirrhosis); pregnancy and breast-feeding.نشرة دولية لنفس التركيبة · European Medicines Agency
- Active pathological bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Lesion or condition at significant risk of major bleeding; concomitant treatment with any other anticoagulant except when switching; hepatic disease associated with coagulopathy (incl. Child-Pugh B and C cirrhosis); pregnancy and breast-feeding.International label, same formulation · European Medicines Agency
تحذيرات واحتياطاتWarnings & precautions
- Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Boxed warning: epidural or spinal haematomas, which may cause long-term or permanent paralysis, can occur with neuraxial anaesthesia or spinal puncture.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Increased risk of bleeding, including serious or fatal bleeding; risk increased with aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Boxed warning: epidural or spinal haematomas, which may cause long-term or permanent paralysis, can occur with neuraxial anaesthesia or spinal puncture.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Increased risk of bleeding, including serious or fatal bleeding; risk increased with aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
التداخلات الدوائيةDrug interactions
- Combined P-gp and strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)Increase rivaroxaban exposure and bleeding risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Combined P-gp and strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampin, St John's wort)Decrease rivaroxaban exposure and may increase thromboembolic risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Anticoagulants, aspirin, clopidogrel and NSAIDsCoadministration may increase bleeding risk; avoid other anticoagulants unless benefit outweighs risk and evaluate promptly any signs of blood loss.DailyMed (U.S. National Library of Medicine)
- Combined P-gp and strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)Increase rivaroxaban exposure and bleeding risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Combined P-gp and strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampin, St John's wort)Decrease rivaroxaban exposure and may increase thromboembolic risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Anticoagulants, aspirin, clopidogrel and NSAIDsCoadministration may increase bleeding risk; avoid other anticoagulants unless benefit outweighs risk and evaluate promptly any signs of blood loss.DailyMed (U.S. National Library of Medicine)
الحمل والرضاعةPregnancy & breastfeeding
- Limited data are insufficient to inform drug-associated developmental risk; use with caution in pregnancy because of potential pregnancy-related haemorrhage and/or emergent delivery.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Contraindicated during pregnancy because of potential reproductive toxicity, intrinsic bleeding risk and placental passage; women of child-bearing potential should avoid becoming pregnant during treatment.نشرة دولية لنفس التركيبة · European Medicines Agency
- Rivaroxaban has been detected in human milk; insufficient data on effects on the breastfed child; weigh benefits of breastfeeding against maternal need.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Limited data are insufficient to inform drug-associated developmental risk; use with caution in pregnancy because of potential pregnancy-related haemorrhage and/or emergent delivery.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Contraindicated during pregnancy because of potential reproductive toxicity, intrinsic bleeding risk and placental passage; women of child-bearing potential should avoid becoming pregnant during treatment.International label, same formulation · European Medicines Agency
- Rivaroxaban has been detected in human milk; insufficient data on effects on the breastfed child; weigh benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)
تابع أسعار الأدوية أول بأول
بننشر كل يوم أسعار أدوية اتغيرت والبدائل الأرخص
المثائل (13)
كل المثائل والبدائلنفس المادة الفعالة والتركيز. اسأل الصيدلي قبل الاستبدال.
| الدواء | السعر | الفرق عن الأصلي |
|---|---|---|
| ريباتوكسابان 10مجم 10 اقراصRepatoxaban 10 mg 10 tabsHorus for Pharmaceutical Products · 10 mgالأرخص | السعر105ج.م10.5ج.م للوحدة | الفرق عن الأصليأرخص 316ج.م (75.1%) |
| اليبروكسابان 10 مجم 10 أقراصEliproxaban 10 mg 10 f.c. tab.Sato Pharma · قرص مغطى بطبقة رقيقة · 10 mg | السعر130ج.م13ج.م للوحدة | الفرق عن الأصليأرخص 291ج.م (69.1%) |
| ثرومكسيبان 10 مجم 10 اقراصThormoxiban 10 mg 10 f.c. tabs.Medizen Pharmaceutical Industries · 10 mg | السعر130ج.م13ج.م للوحدة | الفرق عن الأصليأرخص 291ج.م (69.1%) |
| ثروموكسيبان 10 مجم 10 قرصThromoxiban 10 mg 10 tabsMedizen Pharmaceutical Industries · 10 mg | السعر130ج.م13ج.م للوحدة | الفرق عن الأصليأرخص 291ج.م (69.1%) |
| فاروكسبان 10مجم 10 اقراصVaroxabanEl-Obour · أقراص مغلفة · 10 mg | السعر130ج.م13ج.م للوحدة | الفرق عن الأصليأرخص 291ج.م (69.1%) |
تاريخ السعر
تغيّر السعر الرسمي: من 322 إلى 421 ج.م، 2 أسعار مسجلة
| التاريخ | السعر (ج.م) |
|---|---|
| سعر سابق بدون تاريخ | 322 |
| 421 |
| التاريخ | من | إلى | التغيير |
|---|---|---|---|
| 322ج.م | 421ج.م | زيادة 30.7% |
المعرّفات
- الباركود
- 04008500074763
أدوية ذات صلة
نفس المادة الفعالة بتركيز آخر
منتجات أخرى من Bayer Healthcare
المصادر
- السعر: قوائم أسعار الأدوية المنشورة في مصر.
- DailyMed (U.S. National Library of Medicine)
- European Medicines Agency
تعليقات
لا توجد تعليقات بعد. كن أول من يشارك تجربته مع هذا الدواء.
أضف تعليقًا